ArticleScientific reports2025
Age-stratified analysis of therapeutic, immune, and glycosylation gene expression in colorectal cancer using machine learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Colorectal cancer (CRC) is a major global health issue, yet current treatment strategies rarely consider patient age differences, leading to variable therapeutic efficacy and clinical outcomes. Although numerous biomarkers for CRC have been identified, their age-specific expression profiles and biological implications remain poorly understood. This knowledge gap limits the development and clinical deployment of age-tailored interventions. In this study, we applied an age-aware machine learning framework to uncover gene signatures stratified by age using the GSE44076 microarray dataset. We analyzed three CRC-relevant gene categories (Therapeutic, Immune, and Glycosylation) across three data versions: Original, WithAge (age as a feature), and Age Regressed (residual expression). Patient samples were stratified into younger (< 70 years) and older (≥ 70 years) cohorts to identify age-influenced molecular shifts. Random Forest (RF)-based feature selection yielded compact gene signatures that discriminated against tumor, normal, and mucosa. Under 5 × 10 nested cross-validation, Top-10 gene models achieved Balanced Accuracy ≈ 0.94-0.99 and macro-averaged OvR AUC ≈ 0.96-0.99, while Top-3 sets retained strong performance (Balanced Accuracy ≈ 0.87-0.95). We benchmarked RF against Gradient Boosting Machine (GBM), Support Vector Machine (SVM), and k-Top Scoring Pairs (KTSP) classifiers. RF provided the best overall multivariate metrics under shallow-tree constraints (depth 1-2; min leaf 1-2), KTSP models consistently captured age-dependent gene ranking shifts with enhanced sensitivity, especially in external validation. KTSP's robustness in identifying directional age effects was most evident in the Glycosylation category, where glycan-processing genes showed pronounced age-stratified performance. Permutation tests that replicated the full nested pipeline (N = 100) yielded p≈0.01, confirming that results are unlikely under the null. To uncover deeper regulatory mechanisms, we modeled gene-age interactions, revealing additional biomarkers. External validation using the GSE106582 cohort further supported our findings, although batch harmonization constrained gene coverage by removing platform-unique probes, highlighting a key limitation for microarray-based biomarker translation. Nonetheless, core signatures retained their predictive power, confirming generalizability. Altogether, our results establish age as a critical biological variable influencing CRC gene expression and classifier performance. This study provides a rigorous framework for integrating machine learning, statistical interaction modeling, and biological annotation to guide age-stratified biomarker discovery. Our findings support the development of precision oncology tools tailored to the distinct molecular landscapes of young-onset and late-onset CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.